MicroPort<sup>®</sup> Attends CADECI and Completes First Firehawk® Implantation in Mexico

Guadalajara, Mexico – On February 24, a case using Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") was successfully completed in a local hospital Jardines Hospital de Especialidades in Guadalajara of Mexico during the Mexico International Cardiology Annual Meeting (El Congreso Anual de Cardiología Internacional, CADECI). It is the first implantation of Firehawk® in Mexico following the regulatory approval from the health authority of the Mexican government - the Federal Commission for the Protection against Sanitary Risk (in Spanish, Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS) on January 18. The case was live broadcasted in the CADECI.
 
Jardines Hospital de Especialidades is a famous private hospital in Guadalajara, which boasts for its great medical talents and advanced medical equipment. The Firehawk® case was completed by Dr. Alfredo Rodriguez, a renowned Argentine interventional cardiologist, and CADECI President Dr. Efrain Gaxiola. The patient has LCX stenosis and LAD long calcified diffused lesion. Dr. Alfredo Rodriguez decided to put the wire into distal LAD and successfully implanted three Firehawk® stents - two 27*29mm stents in LAD and one 25*12mm stent in LCX. After the operation, Dr. Rodriguez commented:" Firehawk® has excellent crossability and conformability. In this case, two Firehawk® stents can be easily delivered into the calcified lesion of LAD. After implanting Firehawk®, we find that the stent doesn't have any malapposition under X-ray. I'm very satisfied with the result and so decided that it didn't need post dilatation." Dr. Gaxiola said:" I'm very pleased with the immediate outcome of Firehawk®. I'll follow up this case to make sure its long-term efficacy. I think Firehawk® will become an important product in the Mexico market."
 
In the CADECI, Dr. Alfredo Rodriguez delivered a speech in the main session themed "Innovative Stent," in which he introduced Firehawk®'s main features, innovative design and the results of its TARGET clinical trials. Meanwhile, MicroPort® hosted a dinner party to celebrate the market launch of Firehawk® in Mexico. Jonathan Chen, MicroPort® Executive Vice President of International Operations and Investor Relations, briefed MicroPort®'s development history and its cardiovascular product offerings and highlighted Firehawk®'s advantages. Afterwards, Dr. Alfredo Rodriguez exchanged ideas with local physicians regarding clinical experience in using Firehawk®. The experts in attendance showed great interest in Firehawk®'s unique design and outstanding clinical results, and they looked forward to introducing it to their hospitals.
 
"We are very pleased that our star product Firehawk® is highly recognized in Mexico which is an important market in South America," said Dr. Linda Lin, First Vice President of MicroPort® International Business. "In the future, we hope to bring in more high-quality and high-end medical devices to Mexico to benefit local patients."